RhumbLine Advisers
IPSC icon

RhumbLine Advisers’s Century Therapeutics IPSC Stock Holding History

RhumbLine Advisers’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-43,273
Closed -$20.6K – 4198
2025
Q1 		$20.6K Buy
43,273
+182
+0.4% +$137 ﹤0.01% 3733
2024
Q4 		$43.5K Sell
43,091
-6,771
-14% -$9.22K ﹤0.01% 3677
2024
Q3 		$85.3K Sell
49,862
-2,604
-5% -$5.1K ﹤0.01% 3548
2024
Q2 		$134K Buy
52,466
+18,828
+56% +$59.5K ﹤0.01% 3416
2024
Q1 		$141K Buy
33,638
+692
+2% +$2.93K ﹤0.01% 3331
2023
Q4 		$109K Sell
32,946
-1,256
-4% -$2.29K ﹤0.01% 3422
2023
Q3 		$68.4K Buy
34,202
+750
+2% +$2K ﹤0.01% 3576
2023
Q2 		$106K Buy
33,452
+2,350
+8% +$7.58K ﹤0.01% 3508
2023
Q1 		$108K Buy
31,102
+363
+1% +$1.59K ﹤0.01% 2846
2022
Q4 		$158K Buy
30,739
+222
+0.7% +$2.1K ﹤0.01% 2840
2022
Q3 		$302K Buy
30,517
+1,939
+7% +$20.4K ﹤0.01% 2725
2022
Q2 		$240K Buy
28,578
+13,617
+91% +$134K ﹤0.01% 2857
2022
Q1 		$188K Buy
+14,961
New +$198K ﹤0.01% 2772
2021
Q4 		– Sell
-8,697
Closed -$219K – 3009
2021
Q3 		$219K Buy
+8,697
New +$235K ﹤0.01% 2877

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers's IPSC Position: Q2 2025 in Review

RhumbLine Advisers sold out of Century Therapeutics (IPSC) in Q2 2025, closing a stake of 43,273 shares — an estimated $20.6K sold.

RhumbLine Advisers first reported a position in IPSC in Q3 2021 and held it in 14 quarters. The position peaked at $302K in Q3 2022. 65 funds tracked by Wall St. Rank hold IPSC as of Q2 2025.

  • RhumbLine Advisers reported no remaining Century Therapeutics position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 43,273 Century Therapeutics shares in Q2 2025, an estimated $20.6K.
  • RhumbLine Advisers first reported a position in Century Therapeutics in Q3 2021 and held it in 14 quarters.
  • RhumbLine Advisers's Century Therapeutics position peaked at $302K in Q3 2022.
  • 65 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.